ALNYLAM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense in USD from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2010 to Q3 2025.
  • Alnylam Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $108M, a 136% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $368M, a 65.6% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $272M, a 22.7% increase from 2023.
  • Alnylam Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $222M, a 3.89% decline from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $231M, a 39.2% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $368M $108M +$62.4M +136% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-30
Q2 2025 $306M $112M +$22.4M +25.1% Apr 1, 2025 Jun 30, 2025 10-Q 2025-07-31
Q1 2025 $283M $56.7M +$11.4M +25.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 $272M $91.6M +$49.7M +118% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-13
Q3 2024 $222M $45.8M -$18.1M -28.4% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-30
Q2 2024 $241M $89.3M +$13.5M +17.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-07-31
Q1 2024 $227M $45.3M +$5.4M +13.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q4 2023 $222M $42M -$773K -1.81% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-13
Q3 2023 $222M $63.9M -$64.2M -50.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $287M $75.8M +$45.3M +149% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $241M $39.9M +$10.7M +36.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $231M $42.8M -$1.82M -4.07% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-13
Q3 2022 $232M $128M +$94.8M +284% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $138M $30.5M -$1.61M -5.01% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $139M $29.3M -$26.4M -47.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $166M $44.6M +$10.3M +30.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $155M $33.4M -$3.9M -10.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $159M $32.1M -$1.68M -4.97% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-28
Q1 2021 $161M $55.7M +$21.1M +61.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 $140M $34.3M -$31.9M -48.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $172M $37.3M -$8.75M -19% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $181M $33.8M +$3.15M +10.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $177M $34.6M +$2.55M +7.95% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 $175M $66.2M +$38.2M +137% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-10
Q3 2019 $137M $46M -$41.9M -47.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $179M $30.6M +$8.36M +37.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $170M $32M +$12.4M +63.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $158M $28M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-11
Q3 2018 $88M Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $22.2M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $19.6M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02

ALNYLAM PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $272M +$50.4M +22.7% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-13
2023 $222M -$8.97M -3.89% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-13
2022 $231M +$64.9M +39.2% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-13
2021 $166M +$25.8M +18.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $140M -$35M -20% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $175M +$17.1M +10.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-10
2018 $158M +$64.9M +70% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 $92.8M Jan 1, 2017 Dec 31, 2017 10-K 2020-02-13
2012 $12.7M -$4.4M -25.7% Jan 1, 2012 Dec 31, 2012 10-K 2013-02-19
2011 $17.1M -$2.3M -11.9% Jan 1, 2011 Dec 31, 2011 10-K 2013-02-19
2010 $19.4M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.